Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,311.00-2.62%ETH$2,570.55-4.69%GOLD$4,136.70-1.20%OIL$88.94-0.56%
Smart Investors Daily
SID Premium
GA

NASDAQ · GANX

Gain Therapeutics, Inc.

Healthcare · Biotechnology

$1.67

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 9:18 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
148.53M
P/E ratio
-6.72
Dividend yield
0.00%
52-week range
$1.53 – $3.07
Volume
646.56K
Avg. volume
1.01M

Price performance · GANX

GANX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

GANX closed at $1.67 after 21 trading sessions, down 8.74% for the selected period.

Last close
$1.67
Period change
-8.74%
Period low
$1.67
Period high
$1.95
Daily close
View OHLC price history
GANX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.70$1.75$1.655$1.67646.56K
Oct 5, 2026$1.75$1.77$1.69$1.69351.04K
Oct 2, 2026$1.75$1.78$1.70$1.71386.09K
Oct 1, 2026$1.725$1.7734$1.67$1.72497.41K
Sep 30, 2026$1.70$1.8399$1.69$1.73787.97K
Sep 29, 2026$1.75$1.76$1.60$1.681.29M
Sep 28, 2026$1.75$1.82$1.72$1.77548.02K
Sep 25, 2026$1.85$1.8827$1.775$1.78383.02K
Sep 24, 2026$1.84$1.855$1.79$1.84407.68K
Sep 23, 2026$1.91$1.9733$1.83$1.84292.88K
Sep 22, 2026$1.85$1.96$1.825$1.95692.7K
Sep 21, 2026$1.80$1.85$1.7799$1.84335.86K
Sep 18, 2026$1.79$1.805$1.75$1.76375.55K
Sep 17, 2026$1.77$1.785$1.735$1.78341.54K
Sep 16, 2026$1.73$1.7895$1.70$1.72265.93K
Sep 15, 2026$1.74$1.74$1.69$1.71215.69K
Sep 14, 2026$1.76$1.80$1.73$1.74360.12K
Sep 11, 2026$1.748$1.78$1.72$1.75223.56K
Sep 10, 2026$1.72$1.74$1.69$1.71505.65K
Sep 9, 2026$1.81$1.83$1.72$1.72513.39K
Sep 8, 2026$1.80$1.85$1.77$1.83292.34K

Latest GANX news

The latest Smart Investors Daily articles mentioning GANX.

Stock researchCompany · Overview

GANX research

Overview

Company profile and research snapshot.

Company profile

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.50
Implied upside
—
Analysts
11
GANX recent ratings
DateFirmRatingTarget
Oct 5, 2026HC Wainwright & Co.Buy—
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 11, 2026BTIGBuy—
Jul 1, 2026HC Wainwright & Co.Buy—
Jun 30, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Oct 1, 2026

Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract

Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule

Yahoo · Sep 29, 2026

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. Details of the poster and presentation are as follows: Poster Title: Long-Term Op

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By